Objective-To test the hypothesis that colchicine is an effective treatment of psoriatic arthritis. Methods-Twenty five patients with psoriatic arthritis were entered into a two centre, double blind, crossover study of 23 weeks' duration comparing the therapeutic effect of colchicine (0.6-1.8 mg/day) with placebo. The double blind, randomised, placebo controlled, crossover design of 23 weeks' duration included a one week pretrial washout followed by eight weeks of treatment with placebo or colchicine, then a one week midtrial washout period before switching to the alternative treatment for the second eight week period. This 18 week crossover part of the study was followed by two follow up visits while not receiving the study drugs (post-trial washout) at weeks 19 and 23. The patients were randomised by computer code for their study drugs. Each group began with one tablet a day (either 0-6 mg colchicine or identical placebo) for the first seven days, one tablet twice a day for the second seven days, and then one tablet three times a day for the remaining six weeks. If suspected drug reactions occurred the patient was instructed to decrease the dose to the previous level until the adverse effects were tolerable, and then to try the higher dose again. Those who were unable to tolerate the higher dose rechallenge continued to receive the lower dose. Any patient who was unable to tolerate the drug at 0-6 mg once daily was dropped from the study.
Patients and methods
Patients with arthritis and psoriasis were referred for this study by rheumatologists affiliated with the University of Ottawa rheumatic disease units. Twenty five of the 31 patients referred met the inclusion/exclusion criteria and provided informed consent. The inclusion criteria were: age : 18 years, psoriasis diagnosed by a dermatologist, and active synovitis (tenderness or effusion, or both) in three or more joints. The exclusion criteria were: women with inadequate contraception, history of inflammatory bowel disease, liver disease, renal disease, bone marrow hypoplasia, increased creatine kinase, or a rheumatoid factor (latex) test greater than 1/80. All patients continued existing treatment, including non-steroidal anti-inflammatory drugs (NSAIDs), low doses of prednisone, or low doses of methotrexate at a constant dose for at least three weeks before and during the study period.
STUDY DESIGN
The double blind, randomised, placebo controlled, crossover design of 23 weeks' duration included a one week pretrial washout followed by eight weeks of treatment with placebo or colchicine, then a one week midtrial washout period before switching to the alternative treatment for the second eight week period. This 18 week crossover part of the study was followed by two follow up visits while not receiving the study drugs (post-trial washout) at weeks 19 and 23. The patients were randomised by computer code for their study drugs. Each group began with one tablet a day (either 0-6 mg colchicine or identical placebo) for the first seven days, one tablet twice a day for the second seven days, and then one tablet three times a day for the remaining six weeks. If suspected drug reactions occurred the patient was instructed to decrease the dose to the previous level until the adverse effects were tolerable, and then to try the higher dose again. Those who were unable to tolerate the higher dose rechallenge continued to receive the lower dose. Any patient who was unable to tolerate the drug at 0-6 mg once daily was dropped from the study.
All patients kept daily diaries of concurrent drugs, the study drug regimen, and any perceived adverse effects.
METHODS OF EVALUATION
Clinical evaluations were performed at week 0 (pretrial washout), week 1 number of swollen joints, morning stiffness (minutes), grip strength (using standardised cuff at 20 mmHg), proximal interphalangeal/ distal interphalangeal joint circumference (using an arthrocircumeter), the arthritis impact measurement scales (AIMS) for activities of daily living,5 pain measured on a 0-100 visual analogue scale, and the global assessment (on a four point scale as 1=poor, 2=fair, 3=good, and 4=excellent) by the patient and doctor.
Laboratory evaluations included haemoglobin (mean 140-180 g/l; women 120-160 g/l), white blood cell count (4 0-10 0x 109/1), platelet count (150-400x 109/1), erythrocyte sedimentation rate (men 0-10 mm/h; women 0-20 mm/h Wintrobe), urea (3 5-9-0 mmolIl), creatinine (70-130 ,umol/l), aspartate transaminase (7-40 U/1), alkaline phosphatase (30-110 U/1), and creatine kinase (men 15-170 U/1; women 30-130 U/1). A rheumatoid factor latex fixation test and radiographs of the hands, feet, and sacroiliac joints were obtained at baseline only.
At each visit patients were questioned for possible adverse effects or drug changes. At the end of the study each patient was asked to compare the two treatment periods. improvement in pain on placebo treatment (p=0 022) is not corrected for the number of variables tested. There was no difference in the global assessment or AIMS score between the colchicine and placebo treatment (data not shown). No order effect was detected. Eight patients judged that the placebo and colchicine treatment were equally effective, four preferred colchicine and three preferred the placebo. No change in the skin score for psoriatic rash was noted in either group.
Laboratory measures were unchanged during colchicine treatment with the notable exception of creatine kinase values which increased in 12 of 15 colchicine treatment courses for which creatine kinase values before and after treatment were available (before 101-6 (66 2); after 131-0 (83 5)). The creatine kinase after eight weeks of colchicine treatment exceeded the upper limit of normal (women 130, men 170 U/l) in five patients (396, 200, 552, 277, and 210 U/1). At the end of eight weeks of placebo treatment, however, four patients also had creatine kinase values higher than the upper limit of normal (534, 262, 399, and 228 U/1). No patients reported weakness, and none had the increased serum creatine levels previously associated with an increased risk of colchicine neuromyopathy. We attempted to reproduce Seidman's study using a larger number of patients, the same duration of colchine/placebo treatment, similar entry criteria (though we allowed any concomitant treatment at a constant dose), and similar outcome measures. Unlike Seidman, we used pre-, mid-, and poststudy single blind washout periods. Seidman's study allowed the use of a rescue analgesic (dextropropoxifen 50 mg), though the amount used was not reported.
Unlike Seidman et al we did not find a significant difference between colchicine and placebo treatment using the primary outcome measure (Lansbury joint count) or six of the seven secondary outcome measures. Colchicine was significantly more toxic than placebo with three patients discontinuing colchicine owing to gastrointestinal side effects, usually diarrhoea, abdominal pain, or nausea, or a combination of these. Four of the 10 patients who did not complete the study dropped out in the initial five weeks, precluding their incorporation in a meaningful intent to treat analysis. Our finding of modestly increased creatine kinase levels in the colchicine and placebo treatment groups is unexplained.
The results of Seidman's pilot study might be explained by invoking a type I error. Alternatively, our study is also small and subject to a type II error. The results from 15 patients completing the study could detect a real difference between groups for a Lansbury joint count of 17 or greater (assuming o=0 05 and power=0-8). There was no trend towards a therapeutic effect for colchicine, either by comparing the means before and after treatment for each group, or by using the results of outcome measures for individual patients. For example, only three patients with a 2s-30% improvement in the Lansbury joint count when receiving colchicine also had a s30% improvement while receiving placebo.
In conclusion, our study did not provide evidence that colchicine is therapeutic in psoriatic arthritis.
